



Crown to Cortex

Pharmacology

Final Revision Definitions

The Unhackables Medical
medical.theunhackables.com

How to use this revision PDF

This is the fast recall companion to the full Pharmacology notes. It collects important words, prototype drugs, toxicity signatures, contraindication filters, and exam decision phrases across all 43 topics. It is intentionally compact, but it is not a replacement for the topic PDFs.

First pass

Read each topic's definitions and prototype list.



Second pass

Cover the right column and recall the mechanism or toxicity aloud.



Third pass

Use the contraindication and interaction filters to eliminate options.



Final pass

Review emergency drugs, antidotes, and monitoring points.

Universal pharmacology words

| Word / phrase | Meaning for entrance exams |
|--------------------------|---|
| Prototype drug | The cleanest representative of a class; learn mechanism, use, toxicity, contraindication. |
| Signature toxicity | A recognizable adverse effect that identifies the drug in a vignette. |
| Contraindication filter | A patient factor that makes a usually correct drug wrong. |
| Narrow therapeutic index | Small separation between effective and toxic dose; monitoring is important. |
| First-line | Best usual choice only when no hidden contraindication exists. |
| Empirical therapy | Initial treatment before full confirmation, guided by syndrome and severity. |
| Definitive therapy | Culture, diagnosis, or response-guided targeted treatment. |
| Disease-modifying drug | Improves outcomes or disease course, not only symptoms. |
| Symptomatic drug | Improves symptoms without necessarily changing long-term prognosis. |

Pharmacokinetics

| Term | Definition / exam meaning |
|------------------------|--|
| Absorption | pH partition, gastric emptying, first-pass effect, transporters |
| Distribution | protein binding, Vd, barriers, tissue reservoirs |
| Metabolism | Phase I CYP, Phase II conjugation, prodrugs, active metabolites |
| Excretion | GFR, secretion, reabsorption, urinary pH manipulation |
| High Vd | chloroquine, digoxin, amiodarone |
| Low Vd | heparin, warfarin, aminoglycosides |
| Zero-order | phenytoin, ethanol, aspirin high dose |
| Enzyme induction | rifampicin, carbamazepine, phenytoin, phenobarbitone |
| Enzyme inhibition | macrolides, azoles, ritonavir, cimetidine, grapefruit |
| Bioavailability | Fraction of administered dose reaching systemic circulation unchanged; IV equals 100 percent. |
| Volume of distribution | Apparent space occupied by drug; high Vd suggests tissue binding or lipid solubility. |
| Clearance | Volume of plasma cleared of drug per unit time; maintenance dose depends on clearance. |
| Half-life | Time for plasma concentration to fall by 50 percent; about 4 to 5 half-lives reach steady state. |
| Loading dose | Used when target concentration is needed quickly; depends on Vd and target plasma concentration. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| High Vd | chloroquine, digoxin, amiodarone |
| Low Vd | heparin, warfarin, aminoglycosides |
| Zero-order | phenytoin, ethanol, aspirin high dose |
| Enzyme induction | rifampicin, carbamazepine, phenytoin, phenobarbitone |
| Enzyme inhibition | macrolides, azoles, ritonavir, cimetidine, grapefruit |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Pharmacodynamics

| Term | Definition / exam meaning |
|---------------------------|---|
| Agonist | full, partial, inverse |
| Antagonist | competitive, irreversible, physiological, chemical |
| Receptors | ion channel, GPCR, enzyme-linked, nuclear |
| Dose response | graded and quantal curves |
| Partial agonist | buprenorphine, pindolol, aripiprazole |
| Inverse agonist | many H1 antihistamines, beta-carbolines at GABA-A |
| Competitive antagonist | naloxone, atropine, propranolol |
| Physiological antagonist | adrenaline versus histamine in bronchospasm |
| Potency | Amount of drug required for a given effect; reflected by EC50. |
| Efficacy | Maximum effect a drug can produce; reflected by Emax. |
| Competitive antagonist | Shifts curve right; Emax preserved if enough agonist is added. |
| Noncompetitive antagonist | Reduces Emax; cannot be fully overcome by agonist. |
| Partial agonist | Activates receptor with lower Emax and can antagonize a full agonist. |

Fast toxicity and decision cues

| Cue | Recall |
|--------------------------|---|
| Partial agonist | buprenorphine, pindolol, aripiprazole |
| Inverse agonist | many H1 antihistamines, beta-carbolines at GABA-A |
| Competitive antagonist | naloxone, atropine, propranolol |
| Physiological antagonist | adrenaline versus histamine in bronchospasm |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Clinical Trials

| Term | Definition / exam meaning |
|--------------|---|
| Phase 0 | microdose exploratory PK |
| Phase I | safety, dose, PK |
| Phase II | efficacy signal |
| Phase III | large confirmatory |
| Phase IV | post-marketing surveillance |
| Bias control | randomization, allocation concealment, blinding |
| Analysis | intention-to-treat, per-protocol, subgroup caution |
| Measures | ARR, RRR, NNT, hazard ratio, confidence interval |
| Ethics | consent, equipoise, DSMB, stopping rules |
| Phase 0 | Microdosing; early human pharmacokinetic signal. |
| Phase I | Safety, tolerability, pharmacokinetics; usually healthy volunteers, except toxic drugs such as anticancer agents. |
| Phase II | Efficacy signal and dose ranging in patients. |
| Phase III | Large confirmatory trials for efficacy and safety. |
| Phase IV | Post-marketing surveillance, rare adverse effects, real-world effectiveness. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Bias control | randomization, allocation concealment, blinding |
| Analysis | intention-to-treat, per-protocol, subgroup caution |
| Measures | ARR, RRR, NNT, hazard ratio, confidence interval |
| Ethics | consent, equipoise, DSMB, stopping rules |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

ANS Introduction and Cholinergic Drugs

| Term | Definition / exam meaning |
|------------------------------|--|
| Direct agonists | acetylcholine, bethanechol, carbachol, pilocarpine, cevimeline |
| Reversible AChE inhibitors | neostigmine, pyridostigmine, physostigmine, edrophonium, donepezil, rivastigmine |
| Irreversible AChE inhibitors | organophosphates such as malathion, parathion, echothiophate |
| Antidotes | atropine, pralidoxime, diazepam for seizures |
| Bethanechol | postoperative urinary retention and ileus; avoid asthma and PUD |
| Pilocarpine | glaucoma and xerostomia |
| Neostigmine | MG, ileus, reversal of nondepolarizing block |
| Physostigmine | central anticholinergic toxicity |
| Donepezil | Alzheimer disease symptomatic benefit |
| M1 | CNS and gastric acid secretion. |
| M2 | Heart: decreased SA node firing, AV conduction, and atrial contractility. |
| M3 | Glands, smooth muscle, endothelium; bronchoconstriction, miosis, salivation, sweating. |
| Nn | Autonomic ganglia and adrenal medulla. |
| Nm | Neuromuscular junction. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Bethanechol | postoperative urinary retention and ileus; avoid asthma and PUD |
| Pilocarpine | glaucoma and xerostomia |
| Neostigmine | MG, ileus, reversal of nondepolarizing block |
| Physostigmine | central anticholinergic toxicity |
| Donepezil | Alzheimer disease symptomatic benefit |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Anticholinergic Drugs

| Term | Definition / exam meaning |
|------------------------|--|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Atropine | Bradycardia, organophosphate muscarinic effects, preanesthetic antisialagogue. |
| Ipratropium/tiotropium | Inhaled bronchodilators for COPD and asthma add-on. |
| Tropicamide | Short-acting mydriasis for fundus examination. |
| Scopolamine | Motion sickness; prominent CNS effects. |
| Oxybutynin/tolterodine | Overactive bladder. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Sympathomimetics

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Adrenaline | Anaphylaxis, cardiac arrest, added to local anesthetic. |
| Noradrenaline | Septic shock vasopressor. |
| Dobutamine | Acute heart failure and stress testing. |
| Salbutamol | Acute bronchospasm. |
| Phenylephrine | Pure alpha-1 agonist; nasal decongestant and hypotension. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Sympatholytics

| Term | Definition / exam meaning |
|----------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Prazosin | Selective alpha-1 blocker; hypertension, BPH; first-dose syncope. |
| Phenoxybenzamine | Irreversible alpha blocker; pheochromocytoma preparation. |
| Propranolol | Nonselective beta blocker; migraine, tremor, thyrotoxicosis symptoms. |
| Metoprolol | Beta-1 selective; CAD, HF, hypertension. |
| Labetalol/carvedilol | Alpha plus beta blockade. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

NSAIDs

| Term | Definition / exam meaning |
|----------------------|---|
| Salicylates | aspirin |
| Propionic acids | ibuprofen, naproxen |
| Acetic acids | diclofenac, indomethacin, ketorolac |
| Oxicams | piroxicam, meloxicam |
| COX-2 selective | celecoxib, etoricoxib |
| Para-aminophenol | paracetamol |
| Aspirin | irreversible antiplatelet; ACS, stroke prevention, Kawasaki disease |
| Indomethacin | PDA closure; high toxicity |
| Ketorolac | short-term severe pain only |
| Celecoxib | lower GI ulcer risk but thrombotic caution |
| Paracetamol | NAC-responsive hepatotoxic overdose |
| Aspirin | Irreversible COX inhibition; antiplatelet at low dose. |
| Ibuprofen/naproxen | Reversible nonselective NSAIDs. |
| Indomethacin | Patent ductus arteriosus closure; high GI/CNS toxicity. |
| Celecoxib/etoricoxib | COX-2 selective; less GI toxicity, more thrombotic concern. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Aspirin | irreversible antiplatelet; ACS, stroke prevention, Kawasaki disease |
| Indomethacin | PDA closure; high toxicity |
| Ketorolac | short-term severe pain only |
| Celecoxib | lower GI ulcer risk but thrombotic caution |
| Paracetamol | NAC-responsive hepatotoxic overdose |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Histamine, Serotonin, and Lipid Autacoids

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Gout and Rheumatoid Arthritis

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Feedback | Most endocrine drugs alter hypothalamic-pituitary-target gland loops. |
| Replacement | Physiologic replacement differs from pharmacologic suppression. |
| Monitoring | Use biochemical markers and clinical response together. |
| Emergency | Endocrine crises require route, speed, and supportive care. |
| Pregnancy | Drug choice often changes in pregnancy and lactation. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Diuretics and Antidiuretics

| Term | Definition / exam meaning |
|-------------------------------|---|
| Carbonic anhydrase inhibitors | acetazolamide |
| Loop diuretics | furosemide, torsemide, bumetanide, ethacrynic acid |
| Thiazides | hydrochlorothiazide, chlorthalidone, indapamide |
| K-sparing | spironolactone, eplerenone, amiloride, triamterene |
| Osmotic | mannitol |
| ADH drugs | desmopressin, vaptans, demeclocycline |
| Furosemide | edema, pulmonary edema, hypercalcemia |
| Thiazide | HTN, nephrogenic DI, calcium stone prevention |
| Spirolactone | HF, cirrhosis ascites, hyperaldosteronism |
| Mannitol | raised ICP; avoid pulmonary edema |
| Desmopressin | central DI, vWD, hemophilia A |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Furosemide | edema, pulmonary edema, hypercalcemia |
| Thiazide | HTN, nephrogenic DI, calcium stone prevention |
| Spirolactone | HF, cirrhosis ascites, hyperaldosteronism |
| Mannitol | raised ICP; avoid pulmonary edema |
| Desmopressin | central DI, vWD, hemophilia A |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antihypertensives

| Term | Definition / exam meaning |
|--------------------------|---|
| RAAS blockers | ACE inhibitors, ARBs, aliskiren |
| Calcium channel blockers | dihydropyridines and non-DHP |
| Diuretics | thiazide-like preferred for many patients |
| Beta blockers | selected comorbid indications |
| Vasodilators | hydralazine, minoxidil, nitroprusside |
| Central drugs | clonidine, methyldopa |
| ACE inhibitors | diabetes nephropathy, HF, post-MI; cough/angioedema/hyperkalemia |
| ARBs | ACEI alternative without cough |
| Amlodipine | elderly, isolated systolic HTN; edema |
| Labetalol | pregnancy HTN and hypertensive emergency |
| Nitroprusside | emergency; cyanide/thiocyanate toxicity |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| ACE inhibitors | diabetes nephropathy, HF, post-MI; cough/angioedema/hyperkalemia |
| ARBs | ACEI alternative without cough |
| Amlodipine | elderly, isolated systolic HTN; edema |
| Labetalol | pregnancy HTN and hypertensive emergency |
| Nitroprusside | emergency; cyanide/thiocyanate toxicity |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Anti-anginal Drugs

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Myocardial Infarction and Drugs for Heart Failure

| Term | Definition / exam meaning |
|----------------------------------|---|
| ACS acute | aspirin, P2Y12 blocker, anticoagulation, nitrates, beta blocker, statin, reperfusion |
| HFrEF disease modifying | ARNI/ACEI/ARB, beta blocker, MRA, SGLT2 inhibitor |
| HFrEF symptom relief | loop diuretics, nitrates, hydralazine, digoxin selected |
| Acute HF | oxygen if hypoxic, IV diuretic, vasodilator, inotrope if shock |
| Aspirin | chewed loading in ACS |
| Clopidogrel/prasugrel/ticagrelor | dual antiplatelet with aspirin |
| Enoxaparin/heparin | anticoagulation in ACS |
| Sacubitril-valsartan | mortality benefit in HFrEF |
| Dobutamine | acute decompensated HF with low output |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------------|---|
| Aspirin | chewed loading in ACS |
| Clopidogrel/prasugrel/ticagrelor | dual antiplatelet with aspirin |
| Enoxaparin/heparin | anticoagulation in ACS |
| Sacubitril-valsartan | mortality benefit in HFrEF |
| Dobutamine | acute decompensated HF with low output |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Hypolipidemic Drugs and Antiarrhythmic Drugs

| Term | Definition / exam meaning |
|---------------------------|---|
| Lipid drugs | statins, ezetimibe, PCSK9 inhibitors, fibrates, niacin, bile acid resins, omega-3 |
| Class I antiarrhythmics | Na channel blockers IA/IB/IC |
| Class II | beta blockers |
| Class III | K channel blockers |
| Class IV | verapamil, diltiazem |
| Other | adenosine, digoxin, magnesium |
| Atorvastatin/rosuvastatin | LDL lowering and ASCVD outcome benefit |
| Fenofibrate | hypertriglyceridemia |
| Amiodarone | broad antiarrhythmic; thyroid, lung, liver, cornea toxicity |
| Adenosine | PSVT termination; flushing, bronchospasm |
| Lidocaine | ventricular arrhythmia post-MI |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------------|---|
| Atorvastatin/rosuvastatin | LDL lowering and ASCVD outcome benefit |
| Fenofibrate | hypertriglyceridemia |
| Amiodarone | broad antiarrhythmic; thyroid, lung, liver, cornea toxicity |
| Adenosine | PSVT termination; flushing, bronchospasm |
| Lidocaine | ventricular arrhythmia post-MI |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Sedative Hypnotics, Drugs for Insomnia and Alcohol

| Term | Definition / exam meaning |
|-------------------|---|
| Ion channel drugs | Na, Ca, Cl channels |
| Monoamine drugs | dopamine, serotonin, noradrenaline |
| GABA drugs | benzodiazepines, barbiturates, gabapentinoids |
| Receptor blockers | D2, 5-HT2, muscarinic, NMDA, opioid |
| Benzodiazepines | increase GABA-A frequency; flumazenil reversal selected |
| Levodopa | best symptomatic Parkinson drug; motor fluctuations |
| Opioids | mu agonism; respiratory depression reversed by naloxone |
| Antidepressants | serotonergic and noradrenergic modulation |
| Antipsychotics | D2 blockade or partial agonism with EPS/metabolic tradeoff |
| Target | Ion channels, transporters, GPCRs, and enzymes dominate CNS pharmacology. |
| Latency | Some effects are immediate; antidepressant and antipsychotic benefits often take weeks. |
| Dependence | Sedatives, opioids, and alcohol drugs require withdrawal awareness. |
| Toxicity | CNS drugs are tested through adverse-effect signatures. |
| Interactions | CYP effects and additive CNS depression are common exam traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Benzodiazepines | increase GABA-A frequency; flumazenil reversal selected |
| Levodopa | best symptomatic Parkinson drug; motor fluctuations |
| Opioids | mu agonism; respiratory depression reversed by naloxone |
| Antidepressants | serotonergic and noradrenergic modulation |
| Antipsychotics | D2 blockade or partial agonism with EPS/metabolic tradeoff |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antiepileptic Drugs

| Term | Definition / exam meaning |
|---------------------|---|
| Na channel blockers | phenytoin, carbamazepine, lamotrigine, lacosamide |
| Ca channel drugs | ethosuximide T-type, gabapentin/pregabalin alpha2delta |
| GABA enhancers | benzodiazepines, barbiturates, vigabatrin, tiagabine |
| Broad spectrum | valproate, levetiracetam, topiramate, lamotrigine |
| Special | ethosuximide for absence |
| Valproate | broad spectrum; hepatotoxicity, pancreatitis, teratogenic neural tube defects |
| Phenytoin | gingival hyperplasia, hirsutism, ataxia, CYP induction, fetal hydantoin |
| Carbamazepine | trigeminal neuralgia; SIADH, agranulocytosis, HLA risk |
| Ethosuximide | absence seizures; GI upset |
| Levetiracetam | few interactions; behavioral adverse effects |
| Target | Ion channels, transporters, GPCRs, and enzymes dominate CNS pharmacology. |
| Latency | Some effects are immediate; antidepressant and antipsychotic benefits often take weeks. |
| Dependence | Sedatives, opioids, and alcohol drugs require withdrawal awareness. |
| Toxicity | CNS drugs are tested through adverse-effect signatures. |
| Interactions | CYP effects and additive CNS depression are common exam traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Valproate | broad spectrum; hepatotoxicity, pancreatitis, teratogenic neural tube defects |
| Phenytoin | gingival hyperplasia, hirsutism, ataxia, CYP induction, fetal hydantoin |
| Carbamazepine | trigeminal neuralgia; SIADH, agranulocytosis, HLA risk |
| Ethosuximide | absence seizures; GI upset |
| Levetiracetam | few interactions; behavioral adverse effects |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antipsychotics and Antidepressants

| Term | Definition / exam meaning |
|-------------------------|---|
| Typical antipsychotics | high potency haloperidol; low potency chlorpromazine |
| Atypical antipsychotics | clozapine, risperidone, olanzapine, quetiapine, aripiprazole |
| Antidepressants | SSRIs, SNRIs, TCAs, MAOIs, atypicals |
| Mood stabilizers | lithium, valproate, carbamazepine, lamotrigine |
| Clozapine | treatment-resistant schizophrenia; agranulocytosis, seizures, myocarditis, sialorrhea |
| Haloperidol | acute psychosis; EPS, NMS, QT |
| Fluoxetine/sertraline | SSRIs; sexual dysfunction, GI upset, serotonin syndrome |
| Amitriptyline | TCA; anticholinergic, cardiotoxic overdose |
| Lithium | bipolar; tremor, hypothyroid, nephrogenic DI, Ebstein anomaly |
| Target | Ion channels, transporters, GPCRs, and enzymes dominate CNS pharmacology. |
| Latency | Some effects are immediate; antidepressant and antipsychotic benefits often take weeks. |
| Dependence | Sedatives, opioids, and alcohol drugs require withdrawal awareness. |
| Toxicity | CNS drugs are tested through adverse-effect signatures. |
| Interactions | CYP effects and additive CNS depression are common exam traps. |

Fast toxicity and decision cues

| Cue | Recall |
|-----------------------|---|
| Clozapine | treatment-resistant schizophrenia; agranulocytosis, seizures, myocarditis, sialorrhea |
| Haloperidol | acute psychosis; EPS, NMS, QT |
| Fluoxetine/sertraline | SSRIs; sexual dysfunction, GI upset, serotonin syndrome |
| Amitriptyline | TCA; anticholinergic, cardiotoxic overdose |
| Lithium | bipolar; tremor, hypothyroid, nephrogenic DI, Ebstein anomaly |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Opioids

| Term | Definition / exam meaning |
|-------------------|---|
| Ion channel drugs | Na, Ca, Cl channels |
| Monoamine drugs | dopamine, serotonin, noradrenaline |
| GABA drugs | benzodiazepines, barbiturates, gabapentinoids |
| Receptor blockers | D2, 5-HT2, muscarinic, NMDA, opioid |
| Benzodiazepines | increase GABA-A frequency; flumazenil reversal selected |
| Levodopa | best symptomatic Parkinson drug; motor fluctuations |
| Opioids | mu agonism; respiratory depression reversed by naloxone |
| Antidepressants | serotonergic and noradrenergic modulation |
| Antipsychotics | D2 blockade or partial agonism with EPS/metabolic tradeoff |
| Target | Ion channels, transporters, GPCRs, and enzymes dominate CNS pharmacology. |
| Latency | Some effects are immediate; antidepressant and antipsychotic benefits often take weeks. |
| Dependence | Sedatives, opioids, and alcohol drugs require withdrawal awareness. |
| Toxicity | CNS drugs are tested through adverse-effect signatures. |
| Interactions | CYP effects and additive CNS depression are common exam traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Benzodiazepines | increase GABA-A frequency; flumazenil reversal selected |
| Levodopa | best symptomatic Parkinson drug; motor fluctuations |
| Opioids | mu agonism; respiratory depression reversed by naloxone |
| Antidepressants | serotonergic and noradrenergic modulation |
| Antipsychotics | D2 blockade or partial agonism with EPS/metabolic tradeoff |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Parkinson Disease and Related Disorders

| Term | Definition / exam meaning |
|-------------------|---|
| Ion channel drugs | Na, Ca, Cl channels |
| Monoamine drugs | dopamine, serotonin, noradrenaline |
| GABA drugs | benzodiazepines, barbiturates, gabapentinoids |
| Receptor blockers | D2, 5-HT2, muscarinic, NMDA, opioid |
| Benzodiazepines | increase GABA-A frequency; flumazenil reversal selected |
| Levodopa | best symptomatic Parkinson drug; motor fluctuations |
| Opioids | mu agonism; respiratory depression reversed by naloxone |
| Antidepressants | serotonergic and noradrenergic modulation |
| Antipsychotics | D2 blockade or partial agonism with EPS/metabolic tradeoff |
| Target | Ion channels, transporters, GPCRs, and enzymes dominate CNS pharmacology. |
| Latency | Some effects are immediate; antidepressant and antipsychotic benefits often take weeks. |
| Dependence | Sedatives, opioids, and alcohol drugs require withdrawal awareness. |
| Toxicity | CNS drugs are tested through adverse-effect signatures. |
| Interactions | CYP effects and additive CNS depression are common exam traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Benzodiazepines | increase GABA-A frequency; flumazenil reversal selected |
| Levodopa | best symptomatic Parkinson drug; motor fluctuations |
| Opioids | mu agonism; respiratory depression reversed by naloxone |
| Antidepressants | serotonergic and noradrenergic modulation |
| Antipsychotics | D2 blockade or partial agonism with EPS/metabolic tradeoff |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antithyroid Drugs

| Term | Definition / exam meaning |
|---------------|---|
| Replacement | physiological dosing and monitoring |
| Suppression | block synthesis, release, receptor, or peripheral conversion |
| Sensitization | improve target response |
| Emergency | route and speed dominate exam decisions |
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Feedback | Most endocrine drugs alter hypothalamic-pituitary-target gland loops. |
| Replacement | Physiologic replacement differs from pharmacologic suppression. |
| Monitoring | Use biochemical markers and clinical response together. |
| Emergency | Endocrine crises require route, speed, and supportive care. |
| Pregnancy | Drug choice often changes in pregnancy and lactation. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

HPA Axis and Drugs Acting on Bone and Osteoporosis

| Term | Definition / exam meaning |
|---------------|---|
| Replacement | physiological dosing and monitoring |
| Suppression | block synthesis, release, receptor, or peripheral conversion |
| Sensitization | improve target response |
| Emergency | route and speed dominate exam decisions |
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Feedback | Most endocrine drugs alter hypothalamic-pituitary-target gland loops. |
| Replacement | Physiologic replacement differs from pharmacologic suppression. |
| Monitoring | Use biochemical markers and clinical response together. |
| Emergency | Endocrine crises require route, speed, and supportive care. |
| Pregnancy | Drug choice often changes in pregnancy and lactation. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Oral Hypoglycemic Drugs

| Term | Definition / exam meaning |
|---------------|---|
| Replacement | physiological dosing and monitoring |
| Suppression | block synthesis, release, receptor, or peripheral conversion |
| Sensitization | improve target response |
| Emergency | route and speed dominate exam decisions |
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Feedback | Most endocrine drugs alter hypothalamic-pituitary-target gland loops. |
| Replacement | Physiologic replacement differs from pharmacologic suppression. |
| Monitoring | Use biochemical markers and clinical response together. |
| Emergency | Endocrine crises require route, speed, and supportive care. |
| Pregnancy | Drug choice often changes in pregnancy and lactation. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Parenteral Hypoglycemic Drugs

| Term | Definition / exam meaning |
|---------------|---|
| Replacement | physiological dosing and monitoring |
| Suppression | block synthesis, release, receptor, or peripheral conversion |
| Sensitization | improve target response |
| Emergency | route and speed dominate exam decisions |
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Feedback | Most endocrine drugs alter hypothalamic-pituitary-target gland loops. |
| Replacement | Physiologic replacement differs from pharmacologic suppression. |
| Monitoring | Use biochemical markers and clinical response together. |
| Emergency | Endocrine crises require route, speed, and supportive care. |
| Pregnancy | Drug choice often changes in pregnancy and lactation. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Corticosteroids and Sex Hormones

| Term | Definition / exam meaning |
|---------------|---|
| Replacement | physiological dosing and monitoring |
| Suppression | block synthesis, release, receptor, or peripheral conversion |
| Sensitization | improve target response |
| Emergency | route and speed dominate exam decisions |
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Feedback | Most endocrine drugs alter hypothalamic-pituitary-target gland loops. |
| Replacement | Physiologic replacement differs from pharmacologic suppression. |
| Monitoring | Use biochemical markers and clinical response together. |
| Emergency | Endocrine crises require route, speed, and supportive care. |
| Pregnancy | Drug choice often changes in pregnancy and lactation. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Metformin | AMPK; first-line T2DM; GI upset, lactic acidosis caution |
| Sulfonylureas | close KATP channels; hypoglycemia and weight gain |
| Insulin | essential in T1DM, DKA, pregnancy when needed |
| Steroids | anti-inflammatory genomic effects; adrenal suppression |
| Thyroid drugs | thionamides, iodine, beta blockers, radioiodine, levothyroxine |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Cell Wall Synthesis Inhibitors

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Protein Synthesis Inhibitors

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antimetabolites and Fluoroquinolones

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antiviral Drugs

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antiparasitic and Antiprotozoal Drugs

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antifungal Drugs

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Properties of Antimicrobial Agents

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antimycobacterial Drugs

| Term | Definition / exam meaning |
|----------------------------|---|
| Core map | spectrum, mechanism, resistance, PK/PD, toxicity |
| Resistance | beta-lactamase, target modification, efflux, permeability loss |
| PK/PD | time above MIC versus peak/MIC versus AUC/MIC |
| Stewardship | empirical broad cover followed by culture-guided narrowing |
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Spectrum | Know likely organisms before memorizing names. |
| Resistance | Enzymatic destruction, target change, efflux, reduced permeability. |
| PK/PD | Time-dependent drugs need time above MIC; concentration-dependent drugs need high peak/MIC. |
| Toxicity | Drug-specific toxicity decides exam answers as often as spectrum. |
| Stewardship | Use narrow, effective, shortest rational duration. |

Fast toxicity and decision cues

| Cue | Recall |
|----------------------------|---|
| Beta-lactam logic | cell wall inhibition; allergy and beta-lactamase issues |
| Aminoglycoside logic | concentration-dependent killing; nephro/ototoxicity |
| Macrolide logic | atypical coverage; QT and CYP interactions |
| Fluoroquinolone logic | DNA gyrase/topoisomerase; tendon, QT, cartilage cautions |
| Antiviral/antifungal logic | selective toxicity depends on viral or fungal targets |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Respiratory Pharmacology

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Drugs in Acid Peptic Disease

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Laxative and Antidiarrheal Drugs

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

GIT Drugs

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Antiplatelet and Procoagulants, Thrombolytics and Antithrombolytics

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Oral and Parenteral Anticoagulants

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Hematinics, Iron and Chelators

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Cytotoxic Drugs

| Term | Definition / exam meaning |
|--------------------------|---|
| Alkylators | cyclophosphamide, ifosfamide, busulfan, nitrosoureas, platinum drugs |
| Antimetabolites | methotrexate, 5-FU, cytarabine, gemcitabine, 6-MP |
| Microtubule drugs | vinca alkaloids, taxanes |
| Topoisomerase inhibitors | etoposide, irinotecan, topotecan |
| Antitumor antibiotics | doxorubicin, bleomycin, actinomycin D |
| Cyclophosphamide | hemorrhagic cystitis prevented by mesna |
| Methotrexate | folate antagonist; leucovorin rescue |
| 5-FU | thymidylate synthase inhibition; hand-foot syndrome |
| Vincristine | neurotoxicity, constipation |
| Doxorubicin | cardiomyopathy prevented partly by dexrazoxane |
| Bleomycin | pulmonary fibrosis |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Cyclophosphamide | hemorrhagic cystitis prevented by mesna |
| Methotrexate | folate antagonist; leucovorin rescue |
| 5-FU | thymidylate synthase inhibition; hand-foot syndrome |
| Vincristine | neurotoxicity, constipation |
| Doxorubicin | cardiomyopathy prevented partly by dexrazoxane |
| Bleomycin | pulmonary fibrosis |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Targeted Therapy and Monoclonal Antibodies

| Term | Definition / exam meaning |
|--------------------|---|
| Mechanism | classify by receptor/enzyme/channel/site of action |
| Prototype | learn one clean drug per class |
| Toxicity | signature adverse effects identify the answer |
| Clinical selection | comorbidity and contraindication decide final choice |
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Hemodynamics | Map drug action to preload, afterload, contractility, heart rate, and conduction. |
| Outcomes | Mortality benefit matters more than symptom relief in chronic disease. |
| Electrolytes | Potassium, magnesium, sodium, and calcium strongly affect cardiac drug safety. |
| Contraindications | Asthma, heart block, pregnancy, renal artery stenosis, and shock states are frequent traps. |
| Monitoring | BP, ECG, renal function, electrolytes, INR, and drug levels where relevant. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| First-line | drug used when no special contraindication exists |
| Alternative | used in allergy, pregnancy, organ failure, or resistance |
| Emergency drug | chosen for fast onset and suitable route |
| Antidote | must be memorized with toxicity pattern |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Anesthetic Pharmacology

| Term | Definition / exam meaning |
|------------------------|---|
| Inhalational | sevoflurane, desflurane, isoflurane, nitrous oxide |
| IV induction | propofol, etomidate, ketamine, thiopentone |
| Local anesthetics | esters and amides |
| Neuromuscular blockers | depolarizing succinylcholine; nondepolarizing rocuronium, vecuronium, atracurium |
| Adjuncts | opioids, benzodiazepines, dexmedetomidine |
| Propofol | rapid induction; hypotension, respiratory depression, antiemetic |
| Etomidate | hemodynamic stability; adrenal suppression |
| Ketamine | dissociative anesthesia; bronchodilation, emergence reactions |
| Succinylcholine | rapid paralysis; hyperkalemia, malignant hyperthermia, apnea |
| Bupivacaine | long acting local; cardiotoxicity |
| Target | Ion channels, transporters, GPCRs, and enzymes dominate CNS pharmacology. |
| Latency | Some effects are immediate; antidepressant and antipsychotic benefits often take weeks. |
| Dependence | Sedatives, opioids, and alcohol drugs require withdrawal awareness. |
| Toxicity | CNS drugs are tested through adverse-effect signatures. |
| Interactions | CYP effects and additive CNS depression are common exam traps. |

Fast toxicity and decision cues

| Cue | Recall |
|---------------------|---|
| Propofol | rapid induction; hypotension, respiratory depression, antiemetic |
| Etomidate | hemodynamic stability; adrenal suppression |
| Ketamine | dissociative anesthesia; bronchodilation, emergence reactions |
| Succinylcholine | rapid paralysis; hyperkalemia, malignant hyperthermia, apnea |
| Bupivacaine | long acting local; cardiotoxicity |
| Unsafe-answer check | Pregnancy, renal/hepatic failure, ECG/electrolytes, bleeding risk, respiratory disease, allergy, interaction. |

Final antidote and emergency prompts

| Situation | Drug / action to recall |
|------------------------------------|--|
| Opioid toxicity | Naloxone plus airway and ventilation support. |
| Benzodiazepine toxicity | Supportive care; flumazenil only in selected cases due seizure risk. |
| Organophosphate poisoning | Atropine, pralidoxime early, benzodiazepine for seizures, decontamination. |
| Paracetamol overdose | N-acetylcysteine. |
| Heparin bleeding | Protamine sulfate. |
| Warfarin serious bleeding | Vitamin K plus PCC/FFP depending severity and protocol. |
| Dabigatran bleeding | Idarucizumab where available. |
| Factor Xa inhibitor bleeding | Andexanet alfa where available, or PCC depending protocol. |
| Methotrexate toxicity | Leucovorin rescue; glucarpidase in selected severe toxicity. |
| Cyclophosphamide cystitis | Mesna and hydration. |
| Malignant hyperthermia | Dantrolene and supportive cooling. |
| Local anesthetic systemic toxicity | Lipid emulsion therapy plus resuscitation. |
| Torsades de pointes | IV magnesium, correct potassium, stop QT-prolonging drugs. |